» Articles » PMID: 29181159

Investigation of the Association Between the Polymorphism and Gastric Cancer

Overview
Journal Biomed Rep
Specialty Biochemistry
Date 2017 Nov 29
PMID 29181159
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Murine double minute clone 2 oncoprotein (MDM2) is a key component in the regulation of the tumour suppressor p53. The association between the polymorphism and gastric cancer (GC) has been investigated in Turkish population. In the present case-control study, the aim was to investigate the association between genetic polymorphisms of the gene (a major regulator of p53 function) and primary GC risk in a Turkish population. The polymorphism, (rs2279744) in the gene was determined in patients with GC (n=65) and in healthy control subjects (n=67) using the polymerase chain reaction-restriction fragment length polymorphism method. The findings were evaluated using logistic regression and χ tests. No statistically significant differences were observed between the control subjects and patients with GC regarding smoking status. A comparison between GC cases and control subjects indicated a statistically significant difference for family history of cancer [odds ratio (OR)=0.17; 95% confidence interval (CI), 0.05-0.56; χ=0.19; P=0.01]. A significant difference was identified in the GG genotype distribution between GC patients and control subjects (OR=4.58; 95% CI, 1.18-17.79; P=0.022). Thus, the results of the present study indicate that the gene intron (GG) genotype may be an important risk factor for GC development in the Turkish population.

Citing Articles

Genetic Variations in Gene Contribute to Renal Cell Carcinoma Susceptibility: A Genotype-Phenotype Correlation Study.

Chang S, Chang W, Shih H, Chang C, Wu H, Tsai C Cancers (Basel). 2025; 17(2).

PMID: 39857959 PMC: 11763691. DOI: 10.3390/cancers17020177.


Association of Murine Double Minute 2 polymorphisms with gastric cancer: A systematic review with meta-analysis.

Timoteo M, Tavares A, Cruz S, Campos C, Medeiros R, Sousa H Biomed Rep. 2021; 15(2):69.

PMID: 34257965 PMC: 8243240. DOI: 10.3892/br.2021.1445.


Associations of and Polymorphisms with Early-Stage Breast Cancer.

Bartnykaite A, Savukaityte A, Ugenskiene R, Dauksaite M, Korobeinikova E, Gudaitiene J J Clin Med. 2021; 10(4).

PMID: 33669778 PMC: 7922970. DOI: 10.3390/jcm10040866.


Role of Ala16Val polymorphism in primary brain tumors.

Tas A, Silig Y, Pinarbasi H, GuRelik M Biomed Rep. 2019; 10(3):189-194.

PMID: 30906548 PMC: 6403480. DOI: 10.3892/br.2019.1192.


Association between MDM2 rs2279744, MDM2 rs937283, and p21 rs1801270 polymorphisms and retinoblastoma susceptibility.

Cao Q, Wang Y, Song X, Yang W Medicine (Baltimore). 2018; 97(49):e13547.

PMID: 30544467 PMC: 6314785. DOI: 10.1097/MD.0000000000013547.


References
1.
Tian X, Tian Y, Ma P, Sui C, Meng F, Li Y . Association between MDM2 SNP309 T>G and risk of gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2013; 14(3):1925-9. DOI: 10.7314/apjcp.2013.14.3.1925. View

2.
FREEDMAN D, Wu L, Levine A . Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 1999; 55(1):96-107. PMC: 11146946. DOI: 10.1007/s000180050273. View

3.
Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M . Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature. 2009; 460(7259):1132-5. PMC: 2917235. DOI: 10.1038/nature08235. View

4.
Ventura A, Kirsch D, McLaughlin M, Tuveson D, Grimm J, Lintault L . Restoration of p53 function leads to tumour regression in vivo. Nature. 2007; 445(7128):661-5. DOI: 10.1038/nature05541. View

5.
Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y . MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res. 2007; 13(14):4123-9. DOI: 10.1158/1078-0432.CCR-07-0609. View